$0.56
-0.02 (-2.77%)
Open$0.59
Previous Close$0.58
Day High$0.59
Day Low$0.55
52W High$3.13
52W Low$0.49
Volume—
Avg Volume239.9K
Market Cap19.99M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+734.2% upside
Current
$0.56
$0.56
Target
$4.68
$4.68
$2.81
$4.68 avg
$5.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 25.56M | 26.19M | 3.13M |
| Net Income | -20,526,719 | -18,930,266 | -134,676 |
| Profit Margin | -80.3% | -76.3% | -4.3% |
| EBITDA | -20,922,286 | -20,367,016 | -218,349 |
| Free Cash Flow | — | — | -122,296 |
| Rev Growth | -2.4% | -2.4% | +0.4% |
| Debt/Equity | — | — | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |